Genmab jumps as Rina-S ovarian trial succeeds
Alpha Vantage · Timothy Sykes · · AI-summarised by FinFlash
Genmab shares jumped 9.75% after its Phase 3 RAINFOL-02 trial of Rina-S in platinum-resistant ovarian cancer met primary and secondary endpoints for progression-free and overall survival. Analysts raised price targets, citing the clinical data alongside strong royalty revenue from Johnson & Johnson's DARZALEX. Technical indicators support a continued upward trend.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.